Effectiveness of Ultrasound (US) Guided Supraclavicular Block

Pain Clinical Trial

Official title:

Effectiveness of Ultrasound Guided Supraclavicular Brachial Plexus Block With 20, 30, or 40 ml of Ropivacaine 0.5%

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00923494
• Other study ID #: H-24506
• Status: Withdrawn
• Phase: N/A
• First received: June 16, 2009
• Last updated: January 19, 2017
• Start date: May 2009
• Est. completion date: December 2010

Study information

• Verified date: January 2017
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is being done in order to find out if there is any difference in the effectiveness of ultrasound guided supraclavicular brachial plexus nerve block that can be achieved with 3 different amounts of ropivacaine 0.5% (20 ml, 30 ml, and 40 ml). The investigators want to show if you can have a successful nerve block with less amount of local anesthetic, thus potentially decreasing the risk of side effects.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Patients between the ages of 18-64,

• Patients who are ASA I-III, presenting for distal upper extremity surgery. Surgeries to be considered are ORIF of distal upper extremity fractures such as ORIF radius, ORIF ulna, ORIF of any bones in the wrist or hand, and distal upper extremity surgery involving bones or tendons for which postoperative pain is to be expected. No emergency surgeries will be considered.

Exclusion Criteria:

• Emergency surgery,

• Patient or surgeon refusal

• Patients for which peripheral nerve block or study medications are contraindicated,

• Patients on chronic analgesic therapy at home,

• History of nerve injury, neuropathy, or known neurologic injury or illness, or inability to properly describe postoperative pain to investigators (language barrier, psychiatric disorder, dementia).

Related Conditions & MeSH terms

• Analgesia
• Pain

Intervention

Drug:
• 20 ml of ropivacaine 0.5%
Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
• 30 ml of ropivacaine 0.5%
Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
• 40 ml of ropivacaine 0.5%
Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.

Locations

Country	Name	City	State
United States	Ben Taub General Hospital	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Baylor College of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Onset of analgesia		First 30 minutes
Primary	Duration of analgesia		24 hours
Secondary	Total analgesic use		First 24 hours